Novel directions for diabetes mellitus drug discovery

Expert Opinion on Drug Discovery

Volumn 8, Issue 1, 2013, Pages 35-48

  Maiese, Kenneth ^a,b,c   Chong, Zhao Zhong ^a,c   Shang, Yan Chen ^a,c   Wang, Shaohui ^a,c  

^a Laboratory of Cellular and Molecular Signaling   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c New Jersey Health Sciences University   (United States)

Author keywords

catenin; cell; Akt; Apoptosis; Autophagy; Beclin 1; CCN family; Diabetes mellitus; Erythropoietin; Forkhead transcription factors; FoxO; FRAP1; Glycogen synthase kinase 3 ; Insulin; Mammalian target of rapamycin; Nicotinamide; Nicotinamide adenine dinucleotide; Oxidative stress; Peroxisome proliferators activated receptor; Peroxisome proliferators activated receptor co activator; Phosphoinositide 3 kinase; Poly (ADP ribose) polymerase 1; Programmed cell death; Protein tyrosine phosphatase; SIRT1; Sirtuin; Wingless; Wnt1 inducible signaling pathway protein 1

Indexed keywords

ERYTHROPOIETIN; INSULIN; LEVACECARNINE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE; SIRTUIN 1;

APOPTOSIS; AUTOPHAGY; CELL DAMAGE; CELL SURVIVAL; DIABETES MELLITUS; DRUG DEVELOPMENT; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTRACELLULAR SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; ERYTHROPOIETIN; HUMANS; HYPOGLYCEMIC AGENTS; NIACINAMIDE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84871598393     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.736485     Document Type: Review

References (126)

1. Maiese K, Chong ZZ, Shang YC, et al. Novel Avenues of drug discovery and biomarkers for diabetes mellitus. J Clin Pharmacol 2011;51:128-52
2. Abdullah A, Wolfe R, Mannan H, et al. Epidemiologic merit of obese-years, the combination of degree and duration of obesity. Am J Epidemiol 2012;176(2):99-107
3. Maiese K, Shang YC, Chong ZZ, et al. Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res 2010;7:59-64
4. Reagan LP. Diabetes as a chronic metabolic stressor: causes, consequences and clinical complications. Exp Neurol 2012;233:68-78
5. Maiese K, Chong ZZ, Hou J, et al. Oxidative stress: biomarkers and novel therapeutic pathways. Exp Gerontol 2010;45:217-34
6. Chong ZZ, Shang YC, Wang S, et al. SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets 2012;16:167-78
7. Maiese K, Chong ZZ, Shang YC, et al. Translating cell survival and cell longevity into treatment strategies with SIRT1. Rom J Morphol Embryol 2011;52:1173-85
8. Maiese K, Chong ZZ, Shang YC, et al. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets 2012; [Epub ahead of print]
9. Chong ZZ, Maiese K. Mammalian Target of rapamycin signaling in diabetic cardiovascular disease. Cardiovasc Diabetol 2012;11:45
10. Chong ZZ, Shang YC, Maiese K. Cardiovascular disease and mTOR signaling. Trends Cardiovasc Med 2011;21:151-5
11. Balduini W, Carloni S, Buonocore G. Autophagy in hypoxia-ischemia induced brain injury. J Matern Fetal Neonatal Med 2012;25(Suppl 1):30-4
12. Hyrskyluoto A, Reijonen S, Kivinen J, et al. GADD34 mediates cytoprotective autophagy in mutant huntingtin expressing cells via the mTOR pathway. Exp Cell Res 2012;318:33-42
13. Liu Y, Shi S, Gu Z, et al. Impaired autophagic function in rat islets with aging. Age (Dordr) 2012; [Epub ahead of print]
14. He C, Bassik MC, Moresi V, et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 2012;481:511-15
15. Hu P, Lai D, Lu P, et al. ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. Int J Mol Med 2012;29:613-18
16. Lee Y, Hong Y, Lee SR, et al. Autophagy contributes to retardation of cardiac growth in diabetic rats. Lab Anim Res 2012;28:99-107
17. Martino L, Masini M, Novelli M, et al. Palmitate activates autophagy in INS-1E beta-cells and in isolated rat and human pancreatic islets. PLoS One 2012;7:e36188
18. Fu D Fau-Wu M, Wu M Fau-Zhang J, Zhang J Fau-Du M, et al. Mechanisms of modified LDL-induced pericyte loss and retinal injury in diabetic retinopathy. Diabetologia 2012; [Epub ahead of print]
19. Wang S, Chong ZZ, Shang YC, et al. WISP1 (CCN4) autoregulates its expression and nuclear trafficking of beta-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr Neurovasc Res 2012;9:89-99
20. Troy CM, Akpan N, Jean YY. Regulation of caspases in the nervous system implications for functions in health and disease. Prog Mol Biol Transl Sci 2011;99:265-305
21. Viola G, Bortolozzi R, Hamel E, et al. MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells. Biochem Pharmacol 2012;83:16-26
22. Luo S, Rubinsztein DC. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. Cell Death Differ 2010;17:268-77
23. Kapoor V, Zaharieva MM, Das SN, et al. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma. Cancer Lett 2012;319:39-48
24. Maiese K, Chong ZZ, Hou J, et al. The vitamin nicotinamide: translating nutrition into clinical care. Molecules 2009;14:3446-85
25. Chong ZZ, Lin SH, Maiese K. Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J Vasc Res 2002;39:131-47
26. Chong ZZ, Lin SH, Maiese K. The NAD+ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. J Cereb Blood Flow Metab 2004;24:728-43
27. Chong ZZ, Maiese K. Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways. Curr Neurovasc Res 2008;5:159-70
28. Audrito V, Vaisitti T, Rossi D, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 2011;71:4473-83
29. Ullah N, Ullah I, Lee HY, et al. Protective function of nicotinamide against ketamine-induced apoptotic neurodegeneration in the infant rat brain. J Mol Neurosci 2012;47:67-75
30. Jang Sy Fau-Kang HT, Kang Ht Fau-Hwang ES, Hwang ES. Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation. J Biol Chem 2012;287(23):19304-14
31. Lin SH, Vincent A, Shaw T, et al. Prevention of nitric oxide-induced neuronal injury through the modulation of independent pathways of programmed cell death. J Cereb Blood Flow Metab 2000;20:1380-91
32. Maiese K. Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomed Pharmacother 2008;62:218-32
33. Li F, Chong ZZ, Maiese K. Cell Life Versus Cell Longevity: the Mysteries Surrounding the NAD(+) Precursor Nicotinamide. Curr Med Chem 2006;13:883-95
34. Liu Z, Stanojevic V, Brindamour LJ, et al. GLP1-derived nonapeptide GLP1 (28-36)amide protects pancreatic beta-cells from glucolipotoxicity. J Endocrinol 2012;213:143-54
35. Olmos PR, Hodgson MI, Maiz A, et al. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics. Diabetes Res Clin Pract 2006;71:320-33
36. Crino A, Schiaffini R, Ciampalini P, et al. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2005;18:749-54
37. Eto N, Miyata Y, Ohno H, et al. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005;20:1378-84
38. Stevens MJ, Li F, Drel VR, et al. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J Pharmacol Exp Ther 2007;320:458-64
39. Cresto JC, Fabiano de Bruno LE, Cao GF, et al. The association of acetyl-l-carnitine and nicotinamide remits the experimental diabetes in mice by multiple low-dose streptozotocin. Pancreas 2006;33:403-11
40. Tam D, Tam M, Maynard KI. Nicotinamide modulates energy utilization and improves functional recovery from ischemia in the in vitro rabbit retina. Ann N Y Acad Sci 2005;Aug1053:258-68
41. Kuchmerovska T, Shymanskyy I, Donchenko G, et al. Poly(ADP-ribosyl) ation enhancement in brain cell nuclei is associated with diabetic neuropathy. J Diabetes Complications 2004;18:198-204
42. John CM, Ramasamy R, Al Naqeeb G, et al. Enhanced CD4+CD25+ regulatory T cells with splenic proliferation and protection against oxidative stress by nicotinamide in gestational diabetes. Curr Med Chem 2012; [Epub ahead of print]
43. Swan AA, Chandrashekar R, Beare J, et al. Preclinical efficacy testing in middle-aged rats: nicotinamide, a novel neuroprotectant, demonstrates diminished preclinical efficacy after controlled cortical impact. J Neurotrauma 2011;28:431-40
44. Zhou SS, Li D, Sun WP, et al. Nicotinamide overload may play a role in the development of type 2 diabetes. World J Gastroenterol 2009;15:5674-84
45. Vaca P, Berna G, Araujo R, et al. Nicotinamide induces differentiation of embryonic stem cells into insulin-secreting cells. Exp Cell Res 2008;314:969-74
46. Balan V, Miller GS, Kaplun L, et al. Life span extension and neuronal cell protection by Drosophila nicotinamidase. J Biol Chem 2008;283:27810-19
47. Siegel C, McCullough LD. NAD+ depletion or PAR polymer formation: which plays the role of executioner in ischaemic cell death? Acta Physiol (Oxf) 2011;203:225-34
48. Gale EA, Bingley PJ, Emmett CL, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-31
49. Maiese K, Chong ZZ, Shang YC, et al. Erythropoietin: new directions for the nervous system. Int J Mol Sci 2012;13:11102-29
50. Maiese K, Chong ZZ, Li F, et al. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 2008;85:194-213
51. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. Jama 2005;293:90-5
52. Dang J, Jia R, Tu Y, et al. Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother 2010;64:681-5
53. Hou J, Wang S, Shang YC, et al. Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res 2011;8:220-35
54. Pankratova S, Gu B, Kiryushko D, et al. A new agonist of the erythropoietin receptor, Epobis, induces neurite outgrowth and promotes neuronal survival. J Neurochem 2012;121:915-23
55. Shang YC, Chong ZZ, Wang S, et al. Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) 2012;4:187-201
56. Chong ZZ, Shang YC, Wang S, et al. PRAS40 Is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS ONE 2012;7:e45456
57. Shang YC, Chong ZZ, Wang S, et al. WNT1 Inducible Signaling Pathway Protein 1 (WISP1) Targets PRAS40 to Govern beta-Amyloid Apoptotic Injury of Microglia. Curr Neurovasc Res 2012; [Epub ahead of print]
58. Silverberg DS, Wexler D, Iaina A, et al. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006;26:296-306
59. Singh DK, Winocour P, Farrington K. Erythropoietic stress and anemia in diabetes mellitus. Nat Rev Endocrinol 2009;5:204-10
60. Hamed S, Ullmann Y, Egozi D, et al. Fibronectin potentiates topical erythropoietin-induced wound repair in diabetic mice. J Invest Dermatol 2011;131:1365-74
61. Chu Q, Zhang J, Wu Y, et al. Differential gene expression pattern of diabetic rat retinas after intravitreal injection of erythropoietin. Clin Experiment Ophthalmol 2011;39:142-51
62. Chattopadhyay M, Walter C, Mata M, et al. Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain 2009;132:879-88
63. Choi D, Schroer SA, Lu SY, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 2010;207:2831-42
64. Sinclair AM, Coxon A, McCaffery I, et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010;115:4264-72
65. Chong ZZ, Hou J, Shang YC, et al. EPO Relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3beta, and beta-catenin to foster vascular integrity during experimental diabetes. Curr Neurovasc Res 2011;8:103-20
66. Chong ZZ, Shang YC, Maiese K. Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res 2007;4:194-204
67. Ghaboura N, Tamareille S, Ducluzeau PH, et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Res Cardiol 2011;106:147-62
68. Kelly GS. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev 2010;15:313-28
69. Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007;6:307-19
70. Li Y, Xu S, Giles A, et al. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. Faseb J 2011;25(5):1664-79
71. Frojdo S, Durand C, Molin L, et al. Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1. Mol Cell Endocrinol 2011;335:166-76
72. Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006;4:e31
73. Sasaki T, Kitamura T. Roles of FoxO1 and Sirt1 in the central regulation of food intake. Endocr J 2010;57:939-46
74. Rodgers JT, Lerin C, Haas W, et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005;434:113-18
75. Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009;9:327-38
76. Planavila A, Iglesias R, Giralt M, et al. Sirt1 acts in association with PPAR {alpha} to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 2011;90(2):276-84
77. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol 2007;22:1251-67
78. Hou J, Chong ZZ, Shang YC, et al. Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr Neurovasc Res 2010;7:95-112
79. Sundaresan NR, Pillai VB, Wolfgeher D, et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Science signaling 2011;4:ra46
80. Maiese K, Chong ZZ, Shang YC, et al. A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev 2009;29:395-418
81. Storz P. Forkhead homeobox type O transcription factors in the responses to oxidative stress. Antioxid Redox Signal 2011;14:593-605
82. Kousteni S. FoxO1, the transcriptional chief of staff of energy metabolism. Bone 2012;50:437-43
83. Maiese K, Chong ZZ, Shang YC. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med 2008;14:219-27
84. Wang F, Chan CH, Chen K, et al. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene 2012;31:1546-57
85. Ferrara N, Rinaldi B, Corbi G, et al. Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res 2008;11(1):139-50
86. Xiong S, Salazar G, Patrushev N, et al. FoxO1 Mediates an Autofeedback Loop Regulating SIRT1 Expression. J Biol Chem 2011;286:5289-99
87. Surjana D, Halliday GM, Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J Nucleic Acids 2010;2010
88. Chong ZZ, Shang YC, Wang S, et al. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol 2012; Epub ahead of print
89. Chong ZZ, Shang YC, Zhang L, et al. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev 2010;3:374-91
90. Marfia G, Madaschi L, Marra F, et al. Adult neural precursors isolated from post mortem brain yield mostly neurons: an erythropoietin-dependent process. Neurobiol Dis 2011;43:86-98
91. Sanghera KP, Mathalone N, Baigi R, et al. The PI3K/Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stress. Mol Cell Neurosci 2011;47:145-53
92. Kim J, Jung Y, Sun H, et al. Erythropoietin mediated bone formation is regulated by mTOR signaling. J Cell Biochem 2012;113:220-8
93. Shang YC, Chong ZZ, Wang S, et al. Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia. Curr Neurovasc Res 2011;8:270-85
94. Wang RH, Kim HS, Xiao C, et al. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest 2011;121:4477-90
95. Guo W, Qian L, Zhang J, et al. Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling. J Neurosci Res 2011;89:1723-36
96. Ghosh HS, McBurney M, Robbins PD. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One 2010;5:e9199
97. Zhang S, Cai G, Fu B, et al. SIRT1 is required for the effects of rapamycin on high glucose-inducing mesangial cells senescence. Mech Ageing Dev 2012;133:387-400
98. Hamada S, Hara K, Hamada T, et al. Upregulation of the mammalian target of rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic beta-cells leads to increased beta-cell mass and prevention of hyperglycemia. Diabetes 2009;58:1321-32
99. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945-57
100. Deblon N, Bourgoin L, Veyrat-Durebex C, et al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 2012;165:2325-40
101. Treins C, Alliouachene S, Hassouna R, et al. The combined deletion of S6K1 and Akt2 deteriorates glycaemic control in high fat diet. Mol Cell Biol 2012;32(19):4001-11
102. Maiese K, Li F, Chong ZZ, et al. The Wnt signaling pathway: aging gracefully as a protectionist? Pharmacol Ther 2008;118:58-81
103. Noguti J, CF DEM, Hossaka TA, et al. The role of canonical WNT. signaling pathway in oral carcinogenesis: a comprehensive review. Anticancer Res 2012;32:873-8
104. Lehman DM, Hunt KJ, Leach RJ, et al. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in Mexican Americans. Diabetes 2007;56:389-93
105. Guo YF, Xiong DH, Shen H, et al. Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. J Med Genet 2006;43:798-803
106. Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007;315:1278-82
107. L'Episcopo F, Serapide MF, Tirolo C, et al. A Wnt1 regulated Frizzled-1/beta-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener 2011;6:49
108. Sun J, Jin T. Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells. Cell Signal 2008;20:219-29
109. Berschneider B, Konigshoff M. WNT1 inducible signaling pathway protein 1 (WISP1): a novel mediator linking development and disease. Int J Biochem Cell Biol 2010;43:306-9
110. Macsai CE, Georgiou KR, Foster BK, et al. Microarray expression analysis of genes and pathways involved in growth plate cartilage injury responses and bony repair. Bone 2012;50:1081-91
111. Wang S, Chong ZZ, Shang YC, et al. Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL. Curr Neurovasc Res 2012;9:20-31
112. Lim HW, Lee JE, Shin SJ, et al. Identification of differentially expressed mRNA during pancreas regeneration of rat by mRNA differential display. Biochem Biophys Res Commun 2002;299:806-12
113. Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012;172:761-9
114. Kruger DF. Managing diabetes from first diagnosis: choosing well-tolerated therapies with durability. Diabetes Educ 2012;38:4S-11S
115. Canto C, Houtkooper RH, Pirinen E, et al. The NAD(+) Precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012;15:838-47
116. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 2011;17:6373-80
117. Maiese K, Chong ZZ, Hou J, et al. The "O" class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol 2009;665:242-60
118. Maiese K, Li F, Chong ZZ. Erythropoietin and cancer. JAMA 2005;293:1858-9
119. Miyashita K, Tojo A, Kimura K, et al. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 2004;27:79-84
120. Novak BL, Force RW, Mumford BT, et al. Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature. Pharmacotherapy 2003;23:265-9
121. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature 2008;451:583-6
122. Curran MP. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Paediatr Drugs 2012;14:51-60
123. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11
124. Magri L, Cambiaghi M, Cominelli M, et al. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. Cell Stem Cell 2011;9:447-62
125. Santini E, Heiman M, Greengard P, et al. Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Science signaling 2009;2:ra36
126. Marchand A, Atassi F, Gaaya A, et al. The Wnt/beta-catenin pathway is activated during advanced arterial aging in humans. Aging Cell 2011;10:220-32